Cowen Research Themes 2021 has been published. Click here to learn about the year's key investment themes. >

$150 Million

Krystal Biotech

At-the-market Offering

Krystal Biotech, Inc. is a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction.  Using its patented platform that is based on engineered herpes simplex virus type 1, or HSV-1, Krystal creates vectors that encode functional proteins. Krystal is primarily focused on applying its platform to treat rare monogenic skin conditions caused by insufficient or completely absent protein production. The Company has expanded its pipeline products to develop medicines to treat chronic, non-monogenic skin diseases and aesthetic skin conditions.  Krystal has also started expanding the scope of its product development beyond dermatology and has begun preclinical efforts in the fields of pulmonary diseases.